SML0552
替拉扎明
≥98% (HPLC), Pro-apoptotic, powder
别名:
4-羟基-1-氧-1,2,4-苯并三嗪-1-鎓-3-亚胺, SR 259075, SR 4233, Win 59075, 三嗪酮
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C7H6N4O2
化学文摘社编号:
分子量:
178.15
UNSPSC Code:
12352116
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
替拉扎明, ≥98% (HPLC)
SMILES string
Nc1n[n+]([O-])c2ccccc2[n+]1[O-]
InChI
1S/C7H6N4O2/c8-7-9-11(13)6-4-2-1-3-5(6)10(7)12/h1-4H,(H2,8,9)
InChI key
ORYDPOVDJJZGHQ-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
, orange to dark orange-red
solubility
DMSO: 10 mg/mL, clear
shipped in
wet ice
storage temp.
−20°C
Quality Level
相关类别
Application
已经使用替拉扎明评估其对U-251 MG（成胶质细胞瘤细胞系）细胞活力的细胞毒性作用。
Biochem/physiol Actions
在低氧条件下，替拉扎明是一种有效的细胞毒性剂，通过诱导单链和双链DNA的断裂以及染色体断裂诱导细胞凋亡。 该化合物可使细胞对其他电离辐射和其他细胞毒性药物（如顺铂）敏感。
在缺氧条件下，替拉扎明是有效的细胞毒性药物。
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
J M Brown et al.
Anti-cancer drug design, 13(6), 529-539 (1998-10-02)
Tirapazamine (TPZ, SR 4233, WIN 59075, 3-amino-1,2,4-benzotriazine 1,4-dioxide, Tirazone) is the lead compound in the benzotriazine di-N-oxide class of bioreductive anticancer agents. Extensive preclinical testing has established that the mechanism for the selective toxicity towards hypoxic cells is the result
Goutam Chowdhury et al.
Chemical research in toxicology, 25(1), 197-206 (2011-11-17)
Heterocyclic N-oxides are an interesting class of antitumor agents that selectively kill the hypoxic cells found in solid tumors. The hypoxia-selective activity of the lead compound in this class, tirapazamine, stems from its ability to undergo intracellular one-electron reduction to
Srini B Reddy et al.
Expert opinion on investigational drugs, 18(1), 77-87 (2008-12-05)
Tumor hypoxia remains one of the greatest challenges in the treatment of solid tumors, as cancer cells in these regions are resistant to killing by radiation therapy and most anticancer drugs. Tirapazamine (TPZ) is a newer class of cytotoxic drugs
S Chatterjee et al.
Clinical oncology (Royal College of Radiologists (Great Britain)), 31(8), 510-519 (2019-06-15)
There has been a surge in human papillomavirus (HPV)-positive oropharyngeal cancers (OPCs) in the West. Although the prognosis of HPV-positive OPC is good, de-escalation strategies have so far not been able to confirm comparable cancer control. We examine the strategies
J M Brown
British journal of cancer, 67(6), 1163-1170 (1993-06-01)
SR 4233 (3-amino-1,2,4-benzotriazine 1,4-dioxide, WIN 59075, tirapazamine) is the lead compound in a new class of bioreductive anticancer drugs, the benzotriazine di-N-oxides. It is currently undergoing Phase I clinical testing. The preferential tumour cell killing of SR 4233 is a
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持